Literature DB >> 15089037

Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells.

Sung-Soo Kim1, Pil-Jae Kong, Bong-Seog Kim, Dong-Hyuk Sheen, Su-Youn Nam, Wanjoo Chun.   

Abstract

Microglia are the major inflammatory cells in the central nervous system and become activated in response to brain injuries such as ischemia, trauma, and neurodegenerative diseases including Alzheimer's disease (AD). Moreover, activated microglia are known to release a variety of proinflammatory cytokines and oxidants such as nitric oxide (NO). Minocycline is a semisynthetic second-generation tetracycline that exerts anti-inflammatory effects that are completely distinct form its antimicrobial action. In this study, the inhibitory effects of minocycline on NO and prostaglandin E2 (PGE2) release was examined in lipopolysaccharides (LPS)-challenged BV2 murine microglial cells. Further, effects of minocycline on inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression levels were also determined. The results showed that minocycline significantly inhibited NO and PGE2 production and iNOS and COX-2 expression in BV2 microglial cells. These findings suggest that minocycline should be evaluated as potential therapeutic agent for various pathological conditions due to the excessive activation of microglia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15089037     DOI: 10.1007/bf02980066

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  23 in total

Review 1.  Tetracyclines and pain.

Authors:  Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-27       Impact factor: 3.000

2.  Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans.

Authors:  Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Stephanie S O'Malley
Journal:  Pharmacol Biochem Behav       Date:  2008-11-13       Impact factor: 3.533

Review 3.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 4.  Neurobiology of injury to the developing brain.

Authors:  Wenbin Deng
Journal:  Nat Rev Neurol       Date:  2010-05-18       Impact factor: 42.937

5.  Minocycline impedes African trypanosome invasion of the brain in a murine model.

Authors:  Willias Masocha; Martin E Rottenberg; Krister Kristensson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 6.  Immune-based strategies for mood disorders: facts and challenges.

Authors:  Gabriela D Colpo; Marion Leboyer; Robert Dantzer; Mahdukar H Trivedi; Antonio L Teixeira
Journal:  Expert Rev Neurother       Date:  2017-11-27       Impact factor: 4.618

7.  Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans.

Authors:  Mehmet Sofuoglu; Marc Mooney; Thomas Kosten; Andrew Waters; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2010-09-14       Impact factor: 4.530

8.  A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice.

Authors:  L F S Bastos; A Angusti; M C Vilaça; L A Merlo; E B Nascimento; L T S Rocha; A M Godin; A G R Solano; S Jarussophon; E A Nunan; Y Konishi; M M Coelho
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

9.  Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways.

Authors:  Flávia V Santa-Cecília; Benjamin Socias; Mohand O Ouidja; Julia E Sepulveda-Diaz; Leonardo Acuña; Rangel L Silva; Patrick P Michel; Elaine Del-Bel; Thiago M Cunha; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2016-01-08       Impact factor: 3.911

10.  Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation.

Authors:  Li-ping Yang; Xiu-an Zhu; Mark O M Tso
Journal:  Mol Vis       Date:  2007-07-09       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.